07 September 2020
Visiongain has published a new report on Immunosuppressive Drugs Market Report 2020-2030: Forecasts by Drug Class (Antibodies, Calcineurin Inhibitor, mTOR Inhibitor, Corticosteroids, Others) by Applications (Autoimmune Diseases: Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn’s Disease, Others; Organ Transplant), by Route of Administration (Oral Drugs, Intravenous Drugs), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies). PLUS Profiles of Leading Immunosuppressive Drugs Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global immunosuppressive drugs market was valued at US$ xx billion in 2019 and is projected to reach at a market value of US$ xx billion by 2030. Growing number of organ transplantation procedures; rising prevalence of autoimmune diseases; mounting investment in drug R&D by pharmaceutical and biopharmaceutical companies; and developing healthcare infrastructure in emerging economies are some of the major factors that propel the market growth.
COVID-19 Impact on Immunosuppressive Drugs Market
The COVID-19 pandemic has a significant negative impact on the immunosuppressive drugs market worldwide. This is because any person with an autoimmune disease or chronic medical condition may be considered at increased risk of developing novel coronavirus infection. While the elderly and immune-compromised patients are known to be at the highest risk of complications.
Also, the COVID-19 has greatly impacted solid organ transplantation worldwide and has become a life-threatening danger to organ transplant recipients. The spread of COVID-19 has greatly limited the transplantation system in epidemic areas due to the high risk of infection in immunosuppressed patients, the risk of transmission in health staff, the effect of travel bans on the operations of organ procurement organizations (OPOs) and, under some circumstances, lack of medical services.
Increase in the prevalence of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, psoriasis, Crohn’s disease, and others is a major factor that boosts the demand for immunosuppressive drugs worldwide. In the US, around 8% of the population suffers from autoimmune diseases, of which 78% are women.
Also, the demand for tissue and organ transplant including bone marrow, heart, liver, kidney, and lung is growing worldwide due to the rising number of organ failures. According to the U.S. Department of Health and Human Services, there were over 112,000 patients waiting for the organ transplant in the US as of March 2020. Also, the demand for organs for transplant is increasing because of an increasing aging population worldwide.
Biopharmaceutical and pharmaceutical companies are investing a huge amount of money in R&D of advanced immunosuppressive drugs. There is a high demand for more efficient and reliable immunosuppressants for the treatment of chronic autoimmune diseases and to avoid organ rejection in patients with organ transplantation. According to the study, there were over 500 immunosuppressant products under R&D in 2019.
In addition, the presence of reimbursement policies for covering immunosuppressive drugs for organ transplant recipients could boost the number of transplant procedures. For instance, in the US, immunosuppressive drugs are covered under the immunosuppressive therapy benefit (Social Security Act). To be entitled to reimbursement for the immunosuppressive drugs of a patient, the reasonable and necessary (R&N) conditions set out in the relevant specification of local coverage must be met.
Immunosuppressive drugs market is a highly consolidated market with several global players. Some of the leading players in this market include F. Hoffmann-La Roche AG; GlaxoSmithKline Plc.; Johnson and Johnson; Novartis AG; Eli Lilly and Company; AbbVie; Amgen Inc.; and Bristol Myers Squibb Company.
The major strategies acquired by the leading players are M&A, collaborations, new product launches, high investment in R&D, and geographical expansion. M&A and strategic collaboration help the companies to strengthen their existing product portfolio and geographical reach. Also, this helps companies to strengthen their R&D capabilities, product pipeline, and operational network. For instance, in January 2020, Sanofi completed the acquisition of Synthorx, Inc. for the US $68 per share in cash. The acquisition aligns with Sanofi’s R&D strategy to enhance its position in the area of immunology and oncology. Also, in August 2019, AbbVie announced that the U.S. FDA has approved its RINVOQ (upadacitinib), a once-daily oral JAK inhibitor for the treatment of patients with moderate-to-severe active RA who have had an insufficient response to methotrexate (MTX-IR).
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.
21 September 2022
The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.
16 September 2022
The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.
15 September 2022
The medical device contract manufacturing market was valued at US$69.22 billion in 2021 and is projected to grow at a CAGR of 12.9% during the forecast period 2022-2032.